Table 6.
Descriptive statistics of secondary outcome measured at baseline, 3 month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups
| Secondary Outcomes | TT | NTT | TAU | TT vs NTT | TT vs TAU | NTT vs TAU |
|---|---|---|---|---|---|---|
| Estimated mean (SD) | Estimated mean (SD) | Estimated mean (SD) | Effectsb (95 % CI) | Effectsb (95 % CI) | Effectsc (95 % CI) | |
| ProFitMap intensity | ||||||
| Baseline | 71.64 (11.38) | 71.55 (11.38) | 70 (11.38) | |||
| 3 month | 79.61 (11.02) | 80.84 (11.16) | 72.07 (11.07) | −1.31 (-3 to 5.62) |
5.9 (1.51 to 10.29)** |
7.21 (2.88 to 11.54)** |
| 9 month | 78.48 (11.07) | 81.49 (11.16) | 75.91 (11.24) | −3.09 (-1.22 to 7.40) |
0.92 (-3.49 to 5.33) |
4.01 (-0.32 to 8.34) |
| 15 month | 78.5 (11.02) | 82.1 (11.22) | 76.98 (11.18) | −3.67 (-0.64 to 7.98) |
−0.13 (-4.48 to 4.22) |
3.54 (-0.79 to 7.87) |
| ProFitMap frequency | ||||||
| Baseline | 66.02 (14.67) | 67.74 (14.67) | 64.08 (14.67) | |||
| 3 month | 78.19 (14.05) | 78.69 (14.22) | 67.28 (14.16) | 1.22 (-3.91 to 6.35) |
8.97 (3.74 to 14.2)*** |
7.73 (2.56 to 12.9)** |
| 9 month | 75.74 (14.05) | 76.09 (14.28) | 71.44 (14.25) | 1.38 (-3.75 to 6.51) |
2.36 (-2.85 to 7.57) |
0.98 (-4.19 to 6.15) |
| 15 month | 75.76 (14.05) | 78.73 (14.34) | 72.88 (14.25) | −1.24 (-6.41 to 3.9 ) |
0.95 (-4.26 to 3.61) |
2.19 (-2.98 to 7.36) |
| PGICS | ||||||
| 3 month | 2.20 (1.1) | 2.19 (1.14) | 3.64 (1.1) | 0.01 (-0.52 to 0.54) |
1.44 (0.9 to 1.98)*** |
1.45 (0.93 to 1.97)*** |
| 9 month | 2.5 (1.16) | 2.53 (1.14) | 3.13 (1.18) | 0.04 (-0.49 to 0.57) |
0.8 (0.31 to 1.29)** |
0.85 (0.38 to 1.32)*** |
| 15 month | 2.49 (1.16) | 2.47 (1.14) | 3.18 (1.18) | −0.005 (-0.48 to 0.46) |
0.75 (0.28 to 1.22)** |
0.75 (0.28 to 1.22)** |
| PPT right | ||||||
| Baseline | 223.4 (102.7) | 209.8 (102.8) | 209.2 (102.8) | |||
| 3 month | 251.6 (99.5) | 237 (100.4) | 203.3 (100.2) | 1.03 (-38.4 to 40.4) |
34.1 (-6.1 to 74.3) |
33.06 (-6.6 to 72.8) |
| 9 month | 251.5 (100.1) | 263 (100.5) | 228.4 (102.3) | −25.10 (-65.7 to 14.5) |
8.92 (-31.4 to 49.3) |
34.03 (-5.7 to 73.7) |
| PPT left | ||||||
| Baseline | 218.1 (95.8) | 204.9 (95.8) | 212.3 (95.8) | |||
| 3 month | 247.6 (93.3) | 223.4 (94.1) | 197.3 (94.2) | 11.01 (-28.8 to 50.9) |
44.49 (3.7 to 85.2)* |
33.47 (-6.6 to 73.6) |
| 9 month | 244.8 (94.1) | 243.7 (93.5) | 224.6 (95.6) | −11.99 (-52.1 to 28.1) |
14.46 (-26.3 to 55.2) |
26.45 (-13.65 to 66.6) |
| Work Quantity | ||||||
| Baselined | 8.51 (1.58) | 8.79 (1.58) | 7.95 (1.51) | |||
| 3 month | 9.23 (1.63) | 9.15 (1.56) | 8.91 (1.51) | 0.36 (-0.46 to 1.18) |
−0.25 (-1.07 to 0.57) |
−0.61 (-1.47 to 0.19) |
| 9 month | 9.58 (1.63) | 9.24 (1.56) | 8.94 (1.53) | 0.62 (-0.2 to 1.44) |
0.07 (-0.75 to 0.89) |
−0.55 (-1.16 to 0.25) |
| 15 month | 9.75 (1.63) | 9.09 (1.56) | 9.5 (1.53) | 0.94 (0.12 to 1.76)* |
−0.32 (-1.14 to 0.5) |
−1.26 (-2.06 to -0.46)** |
| Work Quality | ||||||
| Baselinee | 7.43 (1.83) | 8.32 (1.89) | 7.53 (1.86) | |||
| 3 month | 8.77 (1.86) | 9.06 (1.8) | 8.58 (1.74) | 0.61 (-0.31 to 1.53) |
0.28 (-0.64 to 1.2) |
−0.32 (-1.22 to 0.58) |
| 9 month | 9.18 (1.86) | 9.0 (1.8) | 8.52 (1.77) | 1.08 (0.16 to 2)* |
0.76 (-0.16 to 1.68) |
−0.32 (-1.22 to 0.58) |
| 15 month | 9.36 (1.86) | 9.09 (1.8) | 9.11 (1.77) | 1.17 (0.25 to 2.09)* |
0.34 (-0.58 to 1.26) |
−0.82 (-1.72 to 0.08) |
TT tailored treatment group, NTT non-tailored treatment group, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval; PGICS patient global impression of change scale, PPT pressure pain threshold; b Positive values of effects favor the tailored treatment group; c Positive values of effects favor the non-tailored treatment group; d TAU, significant lower (p < 0,05) than NT; e TT, significant lower (p < 0,05) than NTT; * comparison is significant at the 0,05 level, ** comparison is significant at the 0,01 level, *** comparison is significant at the 0,001 level